Home
Live Updates
Instil Bio Reports Fourth Quarter and Full Year 2022 : comparemela.com
Instil Bio Reports Fourth Quarter and Full Year 2022
Instil confirms cash runway beyond 2026 ITIL-306 phase 1 study anticipated to receive CTA clearance from UK MHRA in 2H'2023 Anticipate initial clinical...
Related Keywords
Russia ,
Ukraine ,
United Kingdom ,
Manchester ,
California ,
United States ,
Dallas ,
Texas ,
,
Instil Bio Inc ,
Nasdaq ,
Regulatory Agency ,
Anticipated Milestones ,
Clinical Trial Application ,
Operating Results ,
Ended December ,
Regarding Use ,
Instil Bio ,
Co Stimulatory Antigen Receptor ,
Private Securities Litigation Reform Act ,
Annual Report ,
Nasdaq Til ,
comparemela.com © 2020. All Rights Reserved.